Meta-hydroxyephedrine radioactive tracer
Phase 1Small molecule
Meta-hydroxyephedrine radioactive tracer is one of 21 small molecule programs targeting Ventricular Tachycardia. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Ventricular Tachycardia
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Tambocor
AAlvogen Korea
Approved
Calan
VVal Adams
Approved
Coreg
Akero TherapeuticsApproved
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Mexitil
Boehringer IngelheimApproved
Adenocard
AstellasPhase 3
Drug Treatment
BBiosense Webster, Inc.
Approved
Cordarone
WWyeth-Lederle Vaccines
Phase 3
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- KKhaled Awad, MD